Nathan Denlinger
0000-0002-7936-7547
5 papers found
Refreshing results…
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy
Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma
CAR T-cell therapy for B-cell lymphoma
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
Missing publications? Search for publications with a matching author name.